Insulin-like Growth Factor 1 (IGF-1) measurement is a cornerstone of endocrine laboratory diagnostics, providing a stable and integrated assessment of growth hormone activity. This technical article explains how IGF-1 secretion is evaluated through circulating concentration assays, covering specimen requirements, analytical methods, pre-analytical variables, and clinical applications.
Technical Overview
Insulin-like Growth Factor 1 (IGF-1) is a 70-amino-acid, single-chain polypeptide of approximately 7.6 kDa with structural homology to proinsulin. It is produced predominantly by hepatocytes in response to growth hormone (GH) stimulation. GH released from the anterior pituitary binds hepatic GH receptors and activates the JAK2–STAT5 signaling pathway, which drives IGF-1 gene transcription and secretion into the systemic circulation.
Because IGF-1 has a substantially longer plasma half-life than GH and is secreted in a relatively non-pulsatile manner, a single blood measurement serves as a reliable surrogate marker of integrated 24-hour GH secretion. In circulation, more than 99% of IGF-1 is bound to one of six insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), most notably within a ternary complex composed of IGFBP-3 and the acid-labile subunit (ALS). This binding extends the half-life of the complex to approximately 12–16 hours and stabilizes circulating concentrations.
Interpretation of IGF-1 results must account for strong physiological determinants, including age, pubertal stage, sex, nutritional status, hepatic function, thyroid function, and glycemic control. Concentrations peak during adolescence and decline progressively with age, which is why age- and sex-specific reference intervals are mandatory for clinical reporting.
Testing Samples
Serum
Serum is the standard specimen for clinical IGF-1 measurement. Venous blood is collected into a plain or serum separator tube, allowed to clot for 30 minutes at room temperature, and centrifuged to separate the serum. Fasting collection is recommended, particularly when insulin or glucose is measured concurrently, although IGF-1 concentrations are comparatively stable relative to GH. Serum samples remain stable for approximately 24–72 hours at 2–8°C (assay-dependent) and can be stored long-term at −20°C or −80°C. Repeated freeze–thaw cycles should be avoided.
Plasma
Plasma collected in EDTA or lithium heparin anticoagulant tubes is acceptable on many automated analytical platforms. Results are generally comparable to serum, but laboratories must verify sample-type equivalence for their specific assay and follow manufacturer specifications.
Dried Blood Spots
Dried blood spot specimens are used in pediatric screening programs, population-based epidemiological studies, and remote-site sampling. Their principal advantages are minimal sample volume requirements and stability during ambient-temperature transport, making them well suited for large-scale field research.
Other Specimens
Cerebrospinal fluid, follicular fluid, and cell culture supernatants may be analyzed in specialized research settings. Twenty-four-hour urine collection is not suitable for IGF-1 assessment because intact IGF-1 is not excreted in clinically meaningful quantities by the kidney.
Testing Items
Core analytes associated with IGF-1 secretion assessment include the following:
- Total IGF-1: the primary clinical measurement, reflecting overall GH–IGF axis activity.
- Free (bioavailable) IGF-1: quantifies the unbound fraction with immediate biological activity; primarily a research tool.
- IGFBP-3: the principal binding protein, often measured alongside IGF-1 to evaluate axis integrity.
- IGF-1/IGFBP-3 molar ratio: a calculated index occasionally used to assess bioavailable hormone status.
- IGF-2: measured selectively when non-islet cell tumor hypoglycemia is suspected.
Testing Methods
Clinical IGF-1 quantification is performed almost exclusively by automated non-isotopic immunoassays. Chemiluminescent immunoassay (CLIA) and electrochemiluminescence immunoassay (ECLIA) platforms dominate modern laboratories, employing two-site sandwich immunometric formats with automated pretreatment steps. Manual ELISA kits remain widely used in research environments, whereas radioimmunoassay (RIA), historically performed after acid–ethanol extraction, is now largely obsolete.
A critical analytical challenge is interference from IGFBPs, which can block antibody access to IGF-1 and distort results. Assays address this through acid dissociation, acid–ethanol extraction, or the incorporation of releasing reagents and surfactants that liberate IGF-1 from binding proteins before immunodetection. Validated pretreatment is essential for accurate total IGF-1 measurement.
Liquid chromatography–tandem mass spectrometry (LC-MS/MS) has emerged as a high-specificity alternative, offering minimal cross-reactivity and potential utility as a reference measurement procedure. Regardless of platform, laboratories should calibrate against the WHO International Standard (NIBSC 02/254), maintain intra-assay coefficients of variation typically below 10%, participate in external quality assessment programs, and apply method-specific reference intervals, since inter-method variability remains clinically significant.
Applications
- Diagnosis of acromegaly and gigantly: elevated age-adjusted IGF-1 is a highly sensitive indicator of GH excess.
- Treatment monitoring: serial IGF-1 measurement tracks response to transsphenoidal surgery, somatostatin analogs, GH receptor antagonists, and radiotherapy in acromegaly.
- Pediatric growth assessment: low IGF-1 supports investigation of short stature and suspected growth hormone deficiency, complementing GH stimulation testing.
- Adult growth hormone deficiency: IGF-1 provides supportive evidence alongside provocative GH testing and clinical context.
- Anti-doping surveillance: IGF-1 combined with P-III-NP forms the basis of the World Anti-Doping Agency biomarker approach for detecting recombinant GH abuse.
- Research applications: studies of aging, sarcopenia, caloric restriction, metabolic disease, and cancer epidemiology.
FAQ
Does the test require fasting?
Fasting morning collection is recommended for standardization, but IGF-1 is relatively insensitive to acute dietary intake compared with GH. Severe malnutrition and chronic undernutrition, however, can substantially lower concentrations.
Why measure IGF-1 instead of growth hormone directly?
GH is secreted in pulsatile bursts with a short half-life, so random GH measurements are difficult to interpret. IGF-1 provides a stable, integrated reflection of GH secretion over time, making a single sample diagnostically meaningful.
What conditions can cause falsely low IGF-1?
Malnutrition, chronic liver disease, hypothyroidism, poorly controlled diabetes, acute critical illness, and oral estrogen therapy can all suppress IGF-1 independently of GH status.
How are results interpreted?
Results are compared against age- and sex-specific reference intervals established for the specific assay in use. Elevated levels suggest GH excess, while low levels support GH deficiency or systemic illness, always interpreted alongside clinical findings.
Is a direct secretion rate measurement possible?
In routine clinical practice, no. IGF-1 secretion is assessed indirectly through circulating concentration, which functions as a validated surrogate. Direct secretion kinetics are analyzed only in specialized research settings using deconvolution modeling.
What is the typical turnaround time?
Automated immunoassay platforms typically report results within one to three working days of sample receipt.